

Receipt of Medicinal Cannabis Licenses from the Department of Health

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company') is delighted to announce that it has received the relevant licenses from the Department of Health, Victoria to sell or supply, by wholesale, scheduled cannabinoid substances. Specifically, the licenses includes; Cannabis, Cannabidiol (CBD), Tetrahydrocannabinols (THC) and Dronabinol.

IHL has made arrangements with 3rd party suppliers where necessary to facilitate secure product handling and distribution as per the necessary processes for patient distribution of scheduled cannabinoid medicines. Having the licenses in place facilitates all aspects of Impression's medicinal cannabis activities, including:

- Sales of cannabinoid medicines throughout Australia, where the law permits, under the Special Access Scheme and through the Authorised Prescriber Network
- Import and Export of cannabinoid medicines to and from Australia.

Today's announcement is an important milestone for the Company and complements previously-announced arrangements with AXIM Biotechnologies, Resolution Chemicals and a reputable Canadian manufacturer of cannabis oils and capsules.

Impression Healthcare CEO, Mr Joel Latham said;

"We're delighted to achieve our licencing objectives well ahead of anticipated timing, which is a testament to the quality of our pharmaceutical advisors. Being permitted to sell and supply cannabinoid medicines throughout Australia works to unlock the value in the relationships we have already formed with our proposed suppliers. It also enables the Company to pursue a wider range of opportunities in the emergent cannabis field".

ENDS



Date: 16 January 2019
ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is Australia's largest home dental impression company and is disrupting the dental devices market by providing consumers with an in-home method to consume laboratory-grade and personalised dental healthcare products at significantly lower prices than those offered by the traditional dental industry. Impression has significantly grown its distribution footprint and increased its revenues by 359% in the 2018 Financial Year. With its own dental laboratory in Victoria, Australia Impression offers best in class teeth protection and helps its customers combat bruxism, snoring, mild to moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has also broadened its commitment to disruption in the healthcare sector by pursuing multiple opportunities in the field of medicinal cannabis distribution and development including; a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Inc; a license agreement for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand with Resolution Chemicals Ltd; and an agreement for the distribution of medicinal cannabis oils with a major Canadian manufacturer. Impression will leverage its existing marketing activities to explore opportunities to distribute a range of cannabinoid therapeutic products throughout multiple jurisdictions.

Investors: investors@impression.healthcare

Website: www.impression.healthcare